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Renal diseases in mitochondrial cytopathies are a group of rare diseases that are characterized by frequent multisystemic
involvement and extreme variability of phenotype. Most frequently patients present a tubular defect that is consistent with
complete De Toni-Debr´ e-Fanconi syndrome in most severe forms. More rarely, patients present with chronic tubulointerstitial
nephritis, cystic renal diseases, or primary glomerular involvement. In recent years, two clearly deﬁned entities, namely 3243
A>Gt R N A LEU mutations and coenzyme Q10 biosynthesis defects, have been described. The latter group is particularly important
because it represents the only treatable renal mitochondrial defect. In this paper, the physiopathologic bases of mitochondrial
cytopathies, the diagnostic approaches, and main characteristics of related renal diseases are summarized.
1.The Mitochondrial RespiratoryChain
Mitochondria exertmultiple roles incells;inaddition toATP
synthesis through oxidative phosphorylations (OXPHOS),
they are at the crossroad of numerous metabolic pathways,
contribute to heat production, and control cell-cycle/apop-
tosis and regulation of several anaplerotic reactions [1, 2].
OXPHOS occur within the respiratory chain (RC) that is
composed of four protein complexes (complexes I–IV).
These proteins transfer electrons and protons across the
inner mitochondrial membrane generating the electrochem-
ical gradient for ATP synthesis, which is performed by the
ATP synthase (complex V) (reviewed in [1–4]). Within the
mitochondrial RC, ubiquinone or coenzyme Q10 (CoQ10)
plays a crucial role in accepting and shuttling electrons
(Figure 1)[ 5]. CoQ10 is a ubiquitous lipophylic vitamin-like
substance that is found in high concentrations in tissues with
elevated energy turnover (heart, brain, liver, and kidney). In
humans, CoQ10 iscomprisedofaquinonegroupandatailof
10 isoprenyl units (Figure 1). It is endogenously synthesized
through a multienzyme mitochondrial complex [6], that
is encoded by at least 16 genes (PDSS and COQ genes)
(Figure 1). CoQ10 is also a cofactor for several dehydroge-
nases, a modulator of the mitochondrial permeability transi-
tion pore (MPT) that acts as a gating channel for apoptosis,
a cofactor for pyrimidine biosynthesis, and an important
antioxidant [7]. Approximately 0.2% of oxygen molecules
are not reduced into water during OXPHOS and form
reactive oxygen species (ROS) that can be converted by the
Fentonreactionintohighlyreactivehydroxylradicals(￿OH),
causing oxidative damage of mitochondrial DNA (mtDNA),
peroxidation of lipids and proteins, and activation of the
MPT [1, 2]( Figure 1). Accumulation of free radicals plays
a crucial role in the physiopathology of many mitochondrial
diseases [8]. In normal conditions, ROS are scavenged by
superoxide dismutase, catalase, glutathione peroxidase,
and thioredoxin peroxidase (Figure 1); CoQ10, vitamin C,
vitamin E, and other small molecules also contribute to the
mitochondrial defense arsenal against oxidation [1, 5].
2. Genetics of Mitochondrial Diseases
mtDNA is composed of a 16,569bp circular string that
encodes for 37 genes, including all 22 tRNAs, 2 rRNA2 International Journal of Nephrology
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Figure 1: Schematic representation of diﬀerent metabolic processes involved in cellular energy metabolism. (a) shows the interrelationships
betweentheoxidativepathwaysofglucose,aminoacid,andfattyacid,whichleadtoATPproductioninthemitochondrialRCenzymes(black
box). White lines illustrate the electron ﬂow through CoQ10 in the RC. Dashed lines indicate substrates that generate abnormal metabolites
in mitochondrial cytopathies (i.e., lactate, alanine, organic acids, and acyl-carnitines). (b) shows the enzymatic cascade for the biosynthesis
of CoQ10 from mevalonic acid (left) and the principal mitochondrial enzymes with antioxidant function (right): (1) superoxide dismutase,
(2) thioreductase, (3) glutathione peroxidase, (4) catalase, (5) Fenton reaction, (6) prenyl diphosphate synthetase subunit 1 and 2 (PDSS1
and PDSS2), and (7) CoQ biosynthesis enzymes (COQ2–COQ8).International Journal of Nephrology 3
subunits, and 13 structural proteins of the RC; the remaining
75 proteins that compose the RC and other structural or
functional mitochondrial proteins (more than 1000) are
encoded by nuclear genes [3, 9]. In particular and relevant
to several mitochondrial disorders, the biogenesis of the RC
requires a number of assembly factors that are encoded by
nuclear genes; although these proteins are not structural
components of mature RC complexes, they control correct
folding and maturation of protein subunits, and the delivery
and insertion of prosthetic groups into the holoenzymes of
the RC [10]. Mitochondria are transferred from mothers
to their progeny in the oocyte; therefore, genetic diseases
involvingmitochondrialgenesfollowamaternalinheritance.
The ﬁrst mutations in mitochondrial genes have been
reported in the late 1980s [10–13]. Since then, a large num-
ber of mutations in mtDNA have been reported and are
collected in the MITOMAP human mitochondrial genome
database(http://www.mitomap.org/).Their prevalenceinthe
general population may be as high as 1-2:10000 live births
[14]; mutations can be maternally inherited or sporadic.
In addition, mtDNA disorders can follow a Mendelian
pattern of inheritance if they are secondary to mutations of
nuclear genes that control mtDNA copy number or integrity
[15]. As opposed to nuclear genes, the genetic information
encoded by mtDNA is present in hundreds of copies per
cell; mutations may aﬀect all mtDNA copies (homoplasmy)
or only a portion of the mtDNA endowment of cells
(heteroplasmy). Symptoms of patients with heteroplasmic
mutations depend on the relative proportion between
mutated and wild-type mtDNA copies [8]. Cell dysfunction
generally occurs when the proportion of mutated mtDNA
exceeds a given threshold; tissues with high metabolic rates
such as brain, skeletal muscles, heart, and renal tubules
are particularly exposed [3]. The degree of heteroplasmy
is also variable from oocyte to oocyte, causing signiﬁcant
diﬀerences in disease expression among siblings [15].
Mutations in nuclear DNA may aﬀect genes involved in
mtDNAmaintenanceandreplication,mitochondrialprotein
synthesis, protein subunits of individual complexes (they are
common for complex I, but rare for other RC complexes),
and assembly factors [1, 3]. Despite Mendelian inheritance,
high variability in the clinical expression also characterizes
nuclear mutations. Phenotypes associated with individual
genes, however, tend to be more homogeneous; SURF1
mutations, for example, cause Leigh syndrome, SCO2 muta-
tions are always associated with cardiomyopathy, complex I
deﬁciencies (regardless of the gene involved) tend to present
with isolated encephalopathy, and tubulopathy is a common
feature of BCS1L mutations. Diﬀerences among patients
with mutations in the same gene can be ascribed to the
severity of individual mutations, degree of residual activities,
modulating genes, or to the redundancy of the system [8].
3. ClinicalSymptoms of Mitochondrial
Cytopathies
Nearly all organs can be aﬀected in mitochondrial cytop-
athies, resulting in very heterogeneous clinical presentations.
Skeletal muscles are very frequently aﬀected (myopathy,
hypotonia, and exercise intolerance). Exercise intolerance
is a common complaint that is often mislabeled as “psy-
chogenic,” “chronic fatigue syndrome,” or “rheumatic ﬁbro-
myalgia” [15]. Central nervous symptoms develop over
time in most patients; virtually all types of neurological
symptoms have been described in these disorders, including
apnea, hypotonia, lethargy, psychomotor regression, ataxia,
stroke-likeepisodes,hemiparesis,spasticity,seizures,demen-
tia, leukodystrophy, myoclonus, cortical blindness, migraine,
polyneuropathy (sensory and/or motor), and neurogenic
bladder. Sensorineural deafness and cardiac diseases (myo-
cardiopathy, arrhythmias, and heart block) are also com-
monly observed but may remain subclinical and should
always be excluded. Endocrine complications include diabe-
tes mellitus, hypoparathyroidism, hypothyroidism, hypore-
ninemic hypoaldosteronism, and growth hormone def-
iciency. Gastrointestinal symptoms may be related to liver
dysfunction, to intestinal dysmotility (vomiting, diarrhea,
and pseudoobstruction), or malabsorption. Hematological
signs include sideroblastic anemia, neutropenia, and throm-
bocytopenia. Many patients have ocular problems, includ-
ingprogressiveexternalophthalmoplegia,ophthalmoparesis,
pigmentary retinal degeneration, ptosis, cataract, optic atro-
phy,andblindness. Finally,variousskinandhairlesionshave
also been described [16].
From the renal stand point, patients may present with
signsoftubulopathy,proteinuria,nephroticsyndrome,tubu-
lointerstitial nephritis, cystic kidney disease, myoglobinuria,
or renal failure (see below).
Although the above list of symptoms highlights the ex-
treme variability of phenotypes, a major characteristic of
these diseases is the progressive involvement of diﬀerent or-
gans over time.
To date, more than 40 clinical syndromes have been
described, based on the association of diﬀerent symptoms
[1, 3].
4. DiagnosticApproaches to Mitochondrial
Cytopathies
When suspecting a mitochondrial defect, the ﬁrst step is gen-
erally to measure serum lactate, which is frequently elevated.
In oligosymptomatic renal diseases, serum lactate may be
normal, but urine lactate is generally elevated. Brain lactate
can also be directly measured in the cerebrospinal ﬂuid or
estimated by brain MR spectroscopy. If lactate levels are nor-
mal, further genetic studies are not usually recommended.
The diagnostic workup requires a combination of diﬀerent
approaches, including biochemistry and enzymology analy-
ses,moleculargenetics,pathology(histology,histochemistry,
and electron microscopy), and neuroradiology studies.
Measurement of urine organic acids by gas-chro-
matography/mass spectrometry (GC-MS) represents a help-
ful tool for diagnosing mitochondrial cytopathies (Figure 2).
Impaired RC activity causes the accumulation of reduced
NADH/NADPH promoting the conversion of acetoacetate
into 3OH-butyrate in the mitochondrion and the conversion4 International Journal of Nephrology
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Figure 2: Urine organic acids chromatograms in mitochondrial cytopathies. (a) Control patient. The other panels show the urine
chromatograms of their patients with a mitochondrial cytopathy presenting with a generalized tubular defect (b), with De Toni-Debr´ e-
Fanconi syndrome (c), or with congenital nephritic syndrome (d). Note the marked increase in lactate (L) excretion in all 3 patients,
which was associated with increased urinary excretion of 3-OH-butyrate (B) and 5-oxoproline (O). Other metabolites such as pyruvate
(P), succinate (S), and fumarate (F) may also be found in excess.
of pyruvate into lactate in the cytosol (Figure 1). These com-
pounds are often observed in excess in urines, in association
with intermediary products of the Krebs cycle (e.g., 2-
ketoglutarate, fumarate, malate, or succinate). In some cases,
speciﬁc proﬁles of urinary organic acid in combination with
abnormal patterns of blood acylcarnitines allows the diagno-
sis of speciﬁc defects, such as ethylmalonic encephalopathy
(ETHE) or SUCLA2-, SUCLG1-, and TMEM70-related
diseases [17–20]. In addition, low cytosolic ATP impairs
the activity of the γ-glutamyl cycle, which generates glu-
tathione using the energy provided by the hydrolysis of ATP.
We have observed in several cases of renal mitochondrial
cytopathies increased urinary excretion 5-oxoproline, the
upstream metabolite of the γ-glutamyl cycle; this ﬁnding
is not speciﬁc of mitochondrial dysfunctions but is highly
evocative of a mitochondrial defect if found in conjunction
with high urinary excretion of 3OH-butyrate and lactate.
Further indications may be obtained by quantitative analysis
of plasma aminoacids, which typically shows high alanine
(Figure 1) and/or low citrulline levels [21]. These tests
require specialized laboratories, but represent ﬁrst-line anal-
yses allowing to investigate mitochondrial cytopathies with
minimal invasiveness.
Further investigations usually require to obtain tissue
samples; the general rule is to perform tests on samples
collected from the most aﬀected organs. However, in some
cases, this approach may be unreasonably aggressive, and
studies can be performed on cultured ﬁbroblasts. Measure-
ment of the RC complexes in the kidney, for example, may
require an open surgical biopsy to obtain enough mate-
rial. Similarly, CoQ10 determination has been traditionally
performed on skeletal muscle [22], which is an invasive
procedure in infants. Fortunately, the metabolic defects
observed in skeletal muscles, heart, liver, or kidneys are
generallypresentinﬁbroblasts,whichcanbeeasilyexpanded
and shipped to specialized laboratories for diagnosis. In
addition and contrary to other biopsy specimens, treatment
of metabolic defects (CoQ10 biosynthesis defects, e.g.) can
be started before obtaining a skin biopsy, because oral
supplementations do not inﬂuence the results of analyses
performed on cultured ﬁbroblasts [23, 24].
Several methods have been developed to assess the RC
activity in tissues (reviewed in [25]). Polarographic studies
are usually used to measure oxygen consumption in the
presence of oxidative substrates such as pyruvate, glutamate,
malate, or succinate. Spectrophotometric studies allow to
measure the activity of each RC complex; in addition, they
allow to test the combined activity of [complex II + complex
III] that depends on CoQ10. When the combined activity
of [complex II + complex III] is markedly lower than the
activity of each complex tested separately, results strongly
suggest a ubiquinone biosynthesis defect [26].
Intissuessections,theactivityofmitochondrialenzymes,
such as cytochrome c oxidase (COX) and succinate dehy-
drogenase (SDH), can be easily assessed with histochemistry
techniques [3, 27–29] .T h e s ea s s a y sa r er o u t i n e l yp e r f o r m e d
on frozen muscle biopsy specimens but can also be applied
to other tissues, such as the renal cortex. Because COX is
encoded in part by mtDNA, and SDH is entirely encoded by
nuclear genes, these studies can demonstrate heteroplasmy
by showing cells with high SDH activity secondary to com-
pensatory mitochondrial proliferation and low COX activity
[30]; in other cases, they may show a more diﬀuse decrease
in the activity of both enzymes. Electron microscopy, when
available, generally demonstrates abnormal mitochondria,
proliferation of mitochondria, or mitochondria depletion
(Figure 3). Depletion of mitochondria is particularly appar-
ent in proximal tubular cells, which are very rich in
these organelles; mitochondrial proliferation in podocytes of
patients with steroid-resistant nephritic syndrome (SRNS) is
very evocative of a CoQ10 defect.International Journal of Nephrology 5
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Figure 3: Electron microscopy studies. Two examples of intense proliferation of abnormal mitochondria (swollen mitochondria with
simpliﬁed or absent mitochondrial cristae) in a podocyte of a patient with a CoQ10 biosynthesis defect (a) and in the proximal tubular
cells of a child with severe De Toni-Debr´ e-Fanconi syndrome (b).
5.RenalMitochondrialDiseases
Kidney involvement is more frequently reported in children
than in adults [31]. Several renal diseases have been reported
over the past 2 decades, including tubular disorders,
chronic tubulointerstitial nephritis, cystic renal disease, and
glomerular diseases [31]. In addition, two distinct entities
that have primarily glomerular involvement have been
identiﬁed; these include mtDNA mutations in the tRNALEU
gene and CoQ10 biosynthesis defects.
This paper is restricted to mitochondrial cytopathies
that aﬀect primarily OXPHOS. However, inherited disorders
of mitochondrial fatty acid oxidation can also present
with renal involvement. In a large series of 107 patients,
Saudubray et al. have reported a tubulopathy and transient
renal failure in more than 25% of cases [32]. Since massive
rhabdomyolysis represents a frequent event during episodes
of acute metabolic decompensation, acute renal failure is
generally secondary to myoglobinuria in these patients.
Transient renal tubular acidosis has been observed in carni-
tine palmitoyltransferase type 1 deﬁciency in combination
with Reye-like syndrome [33]. Deﬁciency of carnitine palmi-
toyltransferase II causes a neonatal onset lethal multiorgan
disease with cystic kidney dysplasia associated with dysmor-
phic features, central nervous system malformations, liver
failure, and cardiomyopathy [34, 35]. Similar ﬁndings can be
observed in glutaric aciduria type II (or multiple acyl-CoA
dehydrogenase deﬁciency), an autosomal recessive defect of
mitochondrial energy metabolism [36]. In both conditions,
cystic kidneys can be detected prenatally or at birth through
routine ultrasonography examination, showing hyperechoic
and enlarged kidneys. These abnormalities are also observed
in Zellweger syndrome and other disorders of peroxisomal
β-oxidation suggesting that, regardless of the subcellular
localization of the biochemical defect, abnormalities of fatty
acid oxidation can lead to abnormal organogenesis.
5.1. Tubular Defects. Proximal tubular cells are very rich
in mitochondria. Not surprisingly, the most frequent renal
tubular ﬁnding is a proximal tubular defect, which has
been reported in more than 60 patients; of these, 39 have
been summarized by Niaudet and Rotig in 1997 [31]; 21
additional patients could be identiﬁed in the literature [37–
42], including a large Spanish cohort reported by Mart´ ın-
Hern´ andez et al. in 2005 [43]. In approximately one-
third of patients, the tubulopathy corresponded to overt
De Toni-Debr´ e-Fanconi syndrome. The remaining patients
had more restricted and generally less overt tubular losses
and presented with proximal renal tubular acidosis, gly-
cosuria, hyperphosphaturia, and/or aminoaciduria. Nearly
all patients had extrarenal symptoms, although cases of
isolated tubulopathy have been reported [38, 39], indicating
that serum and urine lactate should be investigated in all
patients presenting with idiopathic De Toni-Debr´ e-Fanconi
syndrome [43]. From a biochemical stand point, the most
frequent ﬁndings are complex III and/or complex IV defects,
followed by complex I defects. From a genetic stand point,
all types of mutations have been reported, but large mtDNA
deletions are particularly frequent. Tubular involvement is
a relatively frequent feature in severe, neonatal-onset RC
defects with autosomal recessive inheritance and multisys-
tem involvement; among genes associated with this phe-
notype are COX10, BCS1L, RRM2B, MRPS22, and SARS2
[44–48]. Symptoms were present in the neonatal period in
one-third of patients and in 80% of cases by 2 years of
age [31]. Renal biopsies, when available, showed chronic
tubulointerstitial changes with damaged proximal tubular
epithelia; electron microscopy often showed proliferation of
abnormal mitochondria (Figure 3)[ 31, 37]. Few patients
with a Bartter-like phenotype have also been reported [30,
49]. Finally, severe hypomagnesemia is often mentioned
in the descriptions of patients with mitochondrial tubu-
lopathies [50].6 International Journal of Nephrology
Of notice, abnormal renal tubular ﬁndings remain
subclinical (or are overlooked because of the prominence
of neurological symptoms) in nearly 2/3 of patients with
tubulopathy [43].
When approaching patients with a mitochondrial tubu-
lopathy, clinicians should keep in mind that mitochondrial
damage can also be secondary to other causes, including
metabolic diseases (tyrosinemia type I, e.g., [51]), drugs
(ifosfamide, e.g., [52]), or toxic agents, in particular heavy
metals (cadmium, e.g., [53] ) .AD eT o n i - D e b r ´ e-Fanconi
syndrome secondary to antimitochondrial antibodies in
two patients with primary biliary cirrhosis has also been
described [54].
5.2. Chronic Tubulointerstitial Nephritis and Cystic Diseases.
Rare cases presenting with chronic renal failure secondary
to tubulointerstitial nephritis, without evidence of a primary
tubular defect, have been reported; they all had extrarenal
symptoms[55–57].Cysticrenalchangeshavealsobeenrarely
described [58–60].
5.3. Sporadic Cases of Glomerular Involvement. Sclerotic
glomerularlesionsareoftendescribedinrenalmitochondrial
diseasesandareprobablysecondarytotubularandtubuloin-
terstitial lesions. At least nine patients presenting with pri-
maryglomerularlesionshavebeendescribedintheliterature
[31, 58, 61–63]. They were generally diagnosed with pro-
teinuria and/or hematuria. Some presented with congenital
nephrotic syndrome. All patients had or developed over time
neurologicalsymptoms(encephalomyopathy);mostpatients
progressed to chronic renal failure if they survived their
extrarenal symptoms. The renal pathology, when available,
was consistent with focal segmental glomerular sclerosis
(FSGS); by EM, depletion or proliferation of abnormal
mitochondria in glomerular cells has been described.
5.4. Renal Disease in tRNALEU Gene Mutations. The 3243
A>G point mutation in the leucine tRNA gene is the
most prevalent mtDNA defect. This mutation was initially
described in children with MELAS syndrome (myopathy,
encephalomyopathy,lacticacidosis,andstroke-likeepisodes)
[2, 3]; however, investigations of mothers that carried
the same mutation showed that the clinical spectrum can
be more restricted to diabetes mellitus, deafness, and/or
neuromuscular symptoms [2, 64]; nearly 1% of the diabetic
population carries this mutation [65]. In 1997, a large
systematic screening of diabetic patients with a history of
maternally inherited diabetes and/or sensorineural hearing
loss showed a disproportional number of patients with end-
stage renal failure secondary to a proteinuric renal disease
in this subset of patients. Since then, at least 27 cases (and
their relatives) have been described [64–72]. Patients with
deafness and proteinuria can also be misleadingly diagnosed
withAlportsyndrome;atotalof90Alportpatientshavebeen
screened in two studies for a MELAS mutation, allowing to
identify 2 misdiagnosed cases [65, 69].
Overall, 2/3 of reported patients are females; diabetes
and/or deafness is generally present in the proband’s mother
and other family members [65, 67–69]. The age at diagnosis
ranges from 14 to 50 years. The prevalent renal pathology
ﬁnding is consistent with FSGS. Four cases of chronic
tubulointerstitial nephritis and one case presenting with
cystic kidney disease have also been described [64, 72]. A
peculiar vasculopathy with hyalinosis of small arteries and
m y o c y t en e c r o s i sh a sb e e nn o t i c e di n2r e p o r t s[ 66, 67].
All patients had high-urinary protein excretion; neph-
rotic syndrome developed in approximately one-third of
cases. Proteinuria generally began in the second or third dec-
ade of life, with the youngest patient diagnosed at the age 5
[64]. Most patients were hypertensive; two female patients
developed pre-eclampsia [66]. Chronic or end-stage renal
failure developed within 10 years in approximately 50% of
cases.
Nearly 80% of patients had sensorineural deafness or
diabetes mellitus at diagnosis; some, in particular younger
patients, developed these symptoms during followup [64–
72]. Other reported ﬁndings include neuromuscular symp-
toms, retinal dystrophy, and cardiomyopathy. Serum lactate
are generally normal.
5.5. CoQ10 Biosynthesis Defects. Primary CoQ10 deﬁciencies
deserve a special place among mitochondrial renal defects
because they represent the only treatable mitochondrial
disorder. They were ﬁrst reported in 1989 in association with
myopathy and encephalopathy [22], and later with cerebellar
ataxia [73].
ThelinkbetweenCoQ10 andrenaldiseasewasestablished
in 2000 when three siblings were diagnosed with pro-
gressive encephalopathy and SRNS; neurological symptoms
improved signiﬁcantly after treatment with oral ubide-
carenone [74]. Two additional siblings that developed SRNS
at 1 year of age were reported in 2005 [75]. The ﬁrst child
developed progressive encephalomyopathy and stroke-like
episodes at 18 months but improved after oral CoQ10 ther-
apy, while the younger sister, who was diagnosed following
herbrotherdisease,wastreatedimmediatelyafterdeveloping
proteinuria and never developed neurological symptoms
[76]. Mutations in the COQ2 gene were identiﬁed in these
two siblings as the ﬁrst report of a genetic defect associated
with primary CoQ10 deﬁciency [77]. COQ2 encodes for
parahydroxybenzoate polyprenyl transferase, the enzyme that
joins the polyprenoid tail to the quinone group of CoQ10
[78]( Figure 1). COQ2 mutations have been found in four
additional patients, all presenting with congenital or early-
onset SRNS [26, 79].
Mutationsintwoothergenesinvolvedinthebiosynthesis
ofCoQ10 havebeenidentiﬁedinpatientswithsimilarclinical
features, namely, in the PDSS2 gene (1 patient) [80]a n d
in the COQ6 gene (11 patients from 5 diﬀerent kindreds)
[81]. Symptoms always began within the ﬁrst years of life;
SRNS was the presenting symptom in most cases, and unless
treated, renal disease progressed to end-stage renal failure
within few years. Other clinical features included deafness
and encephalomyopathy in COQ6 patients; severe forms
with neonatal onset may also present with liver failure and
severe lactic acidosis [26, 79].
Other genes required for CoQ10 biosynthesis can present
with diﬀerent phenotypes: COQ9 mutations, for exampleInternational Journal of Nephrology 7
(1 patient), cause a severe multisystem disorder with a renal
tubulopathy, but no apparent glomerular involvement [82];
patients with mutations in the COQ8 or PDSS1 have no
apparent renal disease [78, 83, 84].
The renal pathology varies from focal segmental glomer-
ulosclerosis to collapsing glomerulopathy [26, 85]; electron
microscopy generally shows numerous dysmorphic mito-
chondria in the cytoplasm of podocytes [26, 85].
Our understanding of CoQ10 has largely beneﬁtted from
the availability of the kd mouse model that recapitulates
the renal phenotype of many CoQ10-deﬁcient patients.
These animals were described in the early 1970s [86], but
their genetic defect was identiﬁed only in 2008, when it
was shown that they harbor a homozygous mutation in
the PDSS2 gene [87]. Kidneys are normal at birth and
developprogressiveinterstitialnephritisassociatedwithfocal
segmental glomerulosclerosis or collapsing glomerulopathy;
most animals progress to end-stage renal disease by 4–8
months of age and die of renal failure [88]. Glomerular
podocytes play a central role in this animal model, while
tubular dilatations and interstitial nephritis represent a
downstream consequence of the glomerular disease, as
demonstrated by conditional knock-out experiments of the
PDSS2 gene in podocytes or tubular cells [87]. Furthermore,
it has been shown that dietary supplementation with CoQ10
prevents proteinuria and renal changes in mutant mice [89].
To date, the pathogenesis of CoQ10 deﬁciency remains
unclear. In particular, the prevalence of lesions in glomerular
cells, which are less energy dependant than tubular cells,
raises the possibility that cell damage may not be entirely
related to the role of CoQ10 in bioenergetics. Silencing the
COQ6 gene in cultured podocytes for example, results in
increased apoptosis [81]. In addition, growth of CoQ10-
deﬁcient ﬁbroblasts can be corrected by uridine, suggest-
ing that impairment of nucleotide metabolism (CoQ10 is
required for the biosynthesis of pyrimidines) may also play
a role in the pathogenesis of these disorders [24]. The
important role of CoQ10 as an antioxidant may also be
responsible for glomerular damage; an inverse relationship
between the severity of CoQ10 deﬁciency and ROS produc-
tion has been demonstrated in patient’s ﬁbroblasts [90, 91];
this hypothesis, however, is not substantiated by in vitro data
showing that quinone analogues such as idebenone, which
are good antioxidants but cannot rescue the mitochondrial
respiratory defect, are probably not eﬀective in the treatment
of these diseases [74, 92]. CoQ10-deﬁcient cells also display
increased autophagy [93]. Finally, a number of studies in kd
miceindicatethatenvironmentalfactorsareimportantinthe
development and progression of renal disease. For example,
it has been shown that calorie restriction dramatically
increases survival of these animals, while protein restriction
has no eﬀect [94]; other studies have shown that placing
mice in a germ-free environment slows disease progression,
underscoring the complexity of factors that are involved in
the pathophysiology of CoQ10 renal defects [95].
Regardless of the mechanisms underlying CoQ10 defects,
one of the most important aspects is the clinical response to
oral supplementations. Initial reports failed to show beneﬁts
on renal lesions because patients had already advanced
kidney disease [74, 75]. Conversely, when treatment was
initiated immediately after the onset of renal symptoms in
one girl, prompt reduction of proteinuria was observed; this
patienthasnormalrenalfunctionnearly8yearsafterstarting
treatment[76].Asimilarresponsehasalsobeendocumented
in 2 patients with COQ6 mutations [81]. Empirically, CoQ10
doses of 30–50mg/Kg/day have been used, but appropriate
pharmacokinetic studies are lacking [76, 81], whereas PDSS2
mutant mice were treated with doses of 200mg/Kg/day [89].
Diﬀerent pharmaceutical formulations are commercially
available; aqueous or oleous suspensions should probably be
preferredtotabletpreparationsthatcontaincrystallineforms
of CoQ10 [96].
In summary, current evidences indicate that ubiquinone
treatment should be started very early to prevent the devel-
opment of irreversible lesions, especially in brain and kid-
neys [76]. A suspicion of a CoQ10 deﬁciency should always
arise in patients with early-onset SRNS, especially when
podocyte mitochondrial abnormalities are observed by elec-
tron microscopy, in the presence of lactic acidosis or when
neurologic or muscular symptoms are present.
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